Rosuvastatin Decreases Mean Platelet Volume in Patients With Diabetes Mellitus

Basit Öğe Kaydı
dc.authorscopusid16315021800
dc.authorscopusid26532378600
dc.authorscopusid56685886500
dc.authorscopusid55881189500
dc.contributor.authorAkyüz, Aydın
dc.contributor.authorAkkoyun, Dursun Çayan
dc.contributor.authorDeğirmenci, Hasan
dc.contributor.authorOran, Mustafa
dc.date.accessioned2022-05-11T14:12:45Z
dc.date.available2022-05-11T14:12:45Z
dc.date.issued2016
dc.departmentFakülteler, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, Kardiyoloji Ana Bilim Dalı
dc.departmentFakülteler, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, İç Hastalıkları Ana Bilim Dalı
dc.description.abstractStatins have multiple effects (also known as pleiotropic effects) on inflammation, plaque stabilization, endothelial function, and hemostasis. We evaluated the effects of rosuvastatin on mean platelet volume (MPV)a marker for platelet activityin patients with diabetes mellitus (DM) on rosuvastatin medication. Patients (n = 178) who were to be prescribed high-intensity rosuvastatin were retrospectively enrolled according to their medical records. Baseline and 6-month biochemical tests, automated blood count, cell-volume analysis, and their cardiovascular risk factors were recorded. Rosuvastatin significantly reduced the MPV and the lipid parameters including total cholesterol, triglyceride, and low-density lipoprotein cholesterol (LDL-C). However, there was no correlation between MPV and LDL-C before (r = -.66; P = .383) and after (r = -.112; P = .135) rosuvastatin treatment or between MPV and LDL-C after 40 mg rosuvastatin daily therapy (r = -.155; P = .073). Rosuvastatin significantly decreases the MPV as well as cholesterol levels. The antiplatelet activation properties of high-dose rosuvastatin treatment in patients with DM are not lipid dependent.
dc.identifier.doi10.1177/0003319715584725
dc.identifier.endpage120
dc.identifier.issn0003-3197
dc.identifier.issn1940-1574
dc.identifier.issue2en_US
dc.identifier.pmid25943745
dc.identifier.scopus2-s2.0-84954198836
dc.identifier.scopusqualityQ2
dc.identifier.startpage116
dc.identifier.urihttps://doi.org/10.1177/0003319715584725
dc.identifier.urihttps://hdl.handle.net/20.500.11776/5663
dc.identifier.volume67
dc.identifier.wosWOS:000369049600004
dc.identifier.wosqualityQ2
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.institutionauthorAkyüz, Aydın
dc.institutionauthorAkkoyun, Dursun Çayan
dc.institutionauthorDeğirmenci, Hasan
dc.institutionauthorOran, Mustafa
dc.language.isoen
dc.publisherSage Publications Inc
dc.relation.ispartofAngiology
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subjectrosuvastatin
dc.subjectmean platelet volume
dc.subjectdiabetes mellitus
dc.subjectcholesterol
dc.subjectCoa Reductase Inhibitor
dc.subjectStatins
dc.subjectCholesterol
dc.subjectExpression
dc.subjectAtherosclerosis
dc.subjectInterleukin-6
dc.subjectMegakaryocyte
dc.subjectHypertension
dc.subjectStroke
dc.subjectAlpha
dc.titleRosuvastatin Decreases Mean Platelet Volume in Patients With Diabetes Mellitus
dc.typeArticle

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
5663.pdf
Boyut:
170.25 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text
İndir

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
Tıp Fakültesi Koleksiyonu